These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 3698461)

  • 1. Interpretation of serum digoxin values in renal failure.
    Gault H; Vasdev S; Vlasses P; Longerich L; Dawe M
    Clin Pharmacol Ther; 1986 May; 39(5):530-6. PubMed ID: 3698461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma endogenous digitalis-like factors in healthy individuals and in dialysis-dependent and kidney transplant patients.
    Vasdev S; Johnson E; Longerich L; Prabhakaran VM; Gault MH
    Clin Nephrol; 1987 Apr; 27(4):169-74. PubMed ID: 3034459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [False results of measuring digoxin levels in patients with renal failure. Comparison of the RIA--FPIA methods].
    Jankowski A; Karwowski J; Marzec A; Kretowicz W; Nartowicz E
    Kardiol Pol; 1990 Feb; 33(2):116-21. PubMed ID: 2277482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation of endogenous digoxin-like immunoreacting activities to salt balance and renal function in man.
    Kramer HJ; Heppe M; Pennig J; Kipnowski J; Klingmüller D; Düsing R; Krück F
    Klin Wochenschr; 1985; 63 Suppl 3():107-10. PubMed ID: 2987606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [ECG changes and serum-digoxin concentration in digitalis toxicity (author's transl)].
    Risler T; Grabensee B; Groose-Brockhoff F
    Dtsch Med Wochenschr; 1975 Apr; 100(15):821-5. PubMed ID: 1122832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interference of digoxin-like immunoreactive substances with three digoxin immunoassays in patients with various degrees of renal function.
    Pleasants RA; Gadsden RH; McCormack JP; Piveral K; Sawyer WT
    Clin Pharm; 1986 Oct; 5(10):810-6. PubMed ID: 3780148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endogenous digoxin-like immunoreactivity in elderly patients with normal serum creatinine concentrations.
    Lackner TE; Lau BW; Parvin C; Valdes R
    Clin Pharm; 1988 Jun; 7(6):449-53. PubMed ID: 3402180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Volume expansion in renal failure patients: a paradigm for a clinically relevant [Na,K]ATPase inhibitor.
    Graves SW; Glatter KA; Lazarus JM; Williams GH; Hollenberg NK
    J Cardiovasc Pharmacol; 1993; 22 Suppl 2():S54-7. PubMed ID: 7508029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tritiated digoxin: studies in renal disease in human subjects.
    Doherty JE; Bissett JK; Kane JJ; de Soyza N; Murphy ML; Flanigan WJ; Dalrymple GV
    Int J Clin Pharmacol Biopharm; 1975 Jul; 12(1-2):89-95. PubMed ID: 1100542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitation of interference in digoxin immunoassay in renal, hepatic, and diabetic disease.
    Tzou MC; Reuning RH; Sams RA
    Clin Pharmacol Ther; 1997 Apr; 61(4):429-41. PubMed ID: 9129560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Falsely elevated plasma aldosterone concentration by direct radioimmunoassay in chronic renal failure.
    Koshida H; Miyamori I; Miyazaki R; Tofuku Y; Takeda R
    J Lab Clin Med; 1989 Sep; 114(3):294-300. PubMed ID: 2769019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Estimating concentrations of serum total digoxin and digoxin-like immunoreactive substances in patients of cardiac failure with renal insufficiency].
    Li JH; Wu ZG; Xu JQ; Zhou Y
    Yao Xue Xue Bao; 1997; 32(3):174-7. PubMed ID: 11327016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential role of parathyroid hormone as an inhibitor of erythropoiesis in the anemia of renal failure.
    McGonigle RJ; Wallin JD; Husserl F; Deftos LJ; Rice JC; O'Neill WJ; Fisher JW
    J Lab Clin Med; 1984 Dec; 104(6):1016-26. PubMed ID: 6501997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of digoxin in Nigerians.
    Iyun AO; Lukanbi FA
    Afr J Med Med Sci; 1988 Mar; 17(1):9-15. PubMed ID: 2834936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Digitalis therapy in renal failure with special regard to digitoxin.
    Vöhringer HF; Rietbrock N
    Int J Clin Pharmacol Ther Toxicol; 1981 Apr; 19(4):175-84. PubMed ID: 7021432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous digoxin-immunoreactive substance measured in several patient populations.
    Valdes R
    Prog Clin Biol Res; 1985; 192():221-8. PubMed ID: 4080710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the volume of distribution of digoxin reduced in patients with renal dysfunction? Determining digoxin pharmacokinetics by fluorescence polarization immunoassay.
    Cheng JW; Charland SL; Shaw LM; Kobrin S; Goldfarb S; Stanek EJ; Spinler SA
    Pharmacotherapy; 1997; 17(3):584-90. PubMed ID: 9165563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Serum digoxin level and renal function].
    Grosse-Brockhoff F; Hengels KJ; Fritsch WP; Grabensee B; Hausamen TU
    Dtsch Med Wochenschr; 1973 Aug; 98(34):1547-51. PubMed ID: 4727386
    [No Abstract]   [Full Text] [Related]  

  • 19. [Use of MDRD equation to detect occult renal failure and reduce the risk of digitalis overdose].
    Cepeda Piorno J; Pobes Martínez de Salinas A; González García ME; Fernández Rodríguez E
    Nefrologia; 2009; 29(2):150-5. PubMed ID: 19396321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic aspects of digoxin in patients with terminal renal failure. I. Off dialysis.
    van der Vijgh WJ
    Int J Clin Pharmacol Biopharm; 1977 Jun; 15(6):249-54. PubMed ID: 881276
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.